Generex to Participate in Canadian Diabetes Association Conference
WORCESTER, Mass., Oct. 20 /PRNewswire/ -- Generex Biotechnology Corporation (Nasdaq: GNBT, www.generex.com) today announced that it will be attending the 13th Annual Canadian Diabetes Association (CDA) (www.diabetes.ca) / Canadian Society of Endocrinology and Metabolism (CSEM) (www.endo-metab.ca) Professional Conference and Annual Meetings in Edmonton, Alberta. The gathering will run from October 20-23, 2010 at the Shaw Conference Centre (9797 Jasper Avenue Northwest, Edmonton).
At booth 437/536, Generex will provide the internationally renowned community of educators, clinicians, and scientists in attendance the chance to learn about the Company's advancements in the field of diabetes. Information and one-on-one Q&A opportunities will be available on Generex Oral-lyn™, the Company's buccal insulin spray, as well as our proprietary consumer product, Glucose RapidSpray™ (www.glucoserapidspray.com).
"This conference is an excellent forum for exchanging ideas and experiences with our peers about how to advance diabetes treatments to the next level," said Mark Fletcher, the Generex Interim President & Chief Executive Officer. "We are particularly looking forward to show-casing Generex Oral-lyn™, which is in the late stages of a global, pivotal Phase III clinical trial."
Highlights of the conference will include speaker forums addressing current diagnosis and treatment issues, interactive workshops, oral abstract sessions, poster presentations, a trade show, and sponsored social activities.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the de